设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 449|回复: 0

淋巴细胞瘤逃避CD-19靶向的嵌合抗原受体修饰的T细胞的进化

[复制链接]
发表于 2015-11-16 22:34:45 | 显示全部楼层 |阅读模式
Evolution to plasmablastic lymphoma evades CD19-direct ed chimeric antigen receptor T cells
Summary
A patient with relapsed and refractory chronic lymphocytic leukaemia with Richter transformation was treated with chimeric antigen receptor (CAR)-modified T cells targeted for CD19 but later relapsed with a clonally related plasmablastic lymphoma. The loss of most routine markers of pre-plasma cell or B lymphoid differentiation(including CD19) highlights the ability of such mature lymphomas to evade lineage-specific targeted immunotherapy by differentiating along pathways comparable to their normal cellular counterparts. Molecular genetic evaluation demonstrated multiple independent lines of CD19-negative disease that eventually evolved in this single patient. Such plasticity represents potential challenges for antigen- directed CAR-T cell therapy, while serving as a testament to the selective pressure exerted by these engineered T cells over time.
Keywords: leukaemia, chronic lymphocytic leukaemia, plasmablastic, lymphoma,
chimeric antigen receptor T cells.
淋巴细胞瘤逃避CD-19靶向的嵌合抗原受体修饰的T细胞的进化
总结:
一个患有复发性和难治性慢性淋巴细胞白血病伴随Richter转化的病人接受CAR修饰的靶向CD19T细胞治疗,但是之后复发了与克隆相关的浆母细胞性淋巴瘤。因为对预浆细胞或B淋巴细胞分化最常规的标记物的损失(包括CD19),通过与正常细胞相比不同的途径,增强了这种成熟淋巴细胞瘤逃脱谱系特异性靶向免疫治疗的能力。分子遗传评价表明CD-19阴型疾病具有多个独立的因素,最终在这个病人身上发生。随着时间的推移,当把这些修饰的T细胞施加的选择性压力作为一种测试的话,这种生物体对环境的适应性意味着着潜在的对CAR-T细胞治疗的挑战。
关键词:白血病,慢性淋巴细胞白血病,淋巴瘤,浆母细胞,嵌合抗原受体的T细胞。

Evolution to plasmablastic lymphoma evades CD19-directed 2015.11.16.pdf

1007.74 KB, 下载次数: 346

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-2-22 16:33 , Processed in 0.101646 second(s), 27 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表